# US 2004/0072736 A1 · Bicyclic oligopeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0072736 A1
- Document ID: US20040072736A1
- Status: Published application
- Kind: A1
- Application number: 10/621,272
- Filed: 2003-07-17
- Published: 2004-04-15
- Earliest claimed: 2002-10-08
- Assignees: Boehringer Ingelheim Pharma GmbH & Co. KG
- Inventors: Olivier Potterat; Ruediger Streicher; Klaus Wagner; Till Maurer; Juergen Mack; Stefan Peters
- Web page: https://patentgrep.com/patent/US20040072736A1

## CPC

- C07K 14/003: {Peptide-nucleic acids (PNAs)}
- C07K 7/56: the cyclisation not occurring through 2,4-diamino-butanoic acid
- C07K 14/605: Glucagons
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to a bicyclic oligopeptide or ester thereof having the capability to inhibit the glucagon receptor, comprised of: (a) a first cyclic group, which comprises at least one cysteine group and is formed by an amide bonding of the N-terminal amino acid with the second carboxylate group of a diacid amino acid, and (b) a second cyclic group which is formed by an amide bonding of an amino acid with the α-carboxylate group of said diacid amino acid, and by a disulfide bonding of the C-terminal cysteine and a cysteine group within the first cyclic group (a); and to the use of such bicyclic oligopeptides for the preparation of a medicament for the treatment or prevention of diseases, in which glucagon receptors are involved.

## Claims

### Claim 1

A bicyclic oligopeptide or ester thereof having the capability to inhibit the glucagon receptor, comprised of
(a) a first cyclic group, which comprises at least one cysteine group and is formed by an amide bonding of the N-terminal amino acid with the second carboxylate group of a diacid amino acid, and
(b) a second cyclic group which is formed by an amide bonding of an amino acid with the α-carboxylate group of said diacid amino acid, and by a disulfide bonding of the C-terminal cysteine and a cysteine group within the first cyclic group (a).

### Claim 2 (depends on 1)

Bicyclic oligopeptide according to claim 1, further comprosed of at least 3 amino acid moieties between the N-terminal amino acid and the said diacid amino acid.

### Claim 3 (depends on 1)

Bicyclic oligopeptide according to claim 1, comprised of at least 4 amino acid moieties between the said diacid amino acid and the C-terminal cysteine.

### Claim 4 (depends on 1)

Bicyclic oligopeptide according claim 1, obtainable by Isolation from a Actinomyces sp and optionally followed by esterification.

### Claim 5 (depends on 4)

Bicyclic oligopeptide according to claim 4, isolated from Streptomyces sp.

### Claim 6 (depends on 5)

Bicyclic oligopeptide according to claim 5, isolated from Streptomyces deposited unter the accession number DSM 14996.

### Claim 7 (depends on 1)

A bicyclic oligopeptide of claim 1, according to formula I,
5
wherein
Xaa1 represents a N-terminal α-amino acid,
Xaa2 represents a diacid amino acid,
Xaa3, Xaa4 and Xaa5 each independently represent an α-amino acid,
m, n and q each independently represent an integer from 2 to 12, and
R represents a hydrogen atom or a C1-6 alkyl group.

### Claim 8 (depends on 7)

Bicyclic oligopeptide of formula I according to claim 7, wherein
Xaa1 represents a N-terminal α-amino acid selected from the group consisting of glycine, alanine, leucine, norleucine and valine,
Xaa2 represents an aspartic or glutamic acid,
Xaa3 each independently represent an α-amino acid selected from the group consisting of glycine, alanine, leucine, norleucine, valine, proline and tryptophan,
Xaa4 each independently represent an α-amino acid selected from the group consisting of glycine, alanine, leucine, norleucine, valine, proline and serine, and
Xaa5 each independently represent an α-amino acid selected from the group consisting of glycine, alanine, isoleucine, leucine, norleucine, valine, proline, threonine, asparagine, tryptophan and serine,
m represents an integer from 3 to 6,
n represents an integer from 2 to 4,
q represents an integer from 6 to 12, and
R represents a hydrogen atom or a methyl group.

### Claim 9 (depends on 1)

Bicyclic oligopeptide according to claim 1, wherein each amino acid exists in the (L)-configuration.

### Claim 10 (depends on 1)

Bicyclic nonadecapeptide according to claim 1, characterized by the following sequence (SEQ ID NO. 1):
6
wherein
the amino group of Gly1 is linked with the β-carboxylate group of Asp9 via an amide group, and
the thiole groups of the cysteines Cys6 und Cys19 are linked via a disulfide bridge.

### Claim 11 (depends on 1)

A medicament comprised of a bicyclic oligopeptide according to claim 1.

### Claim 12 (depends on 1)

Pharmaceutical composition comprising at least one bicyclic oligopeptide according to claim 1, and a pharmacologically acceptable carrier.

### Claim 13 (depends on 12)

Pharmaceutical composition according to claim 12 further comprised of an active ingredient selected from the group consisting of antidiabetic agents, lipid modulating agents, anti-obesity agents and cardiovascular agents.

### Claim 14 (depends on 13)

Pharmaceutical composition according to claim 13, wherein the antidiabetic agent is selected from the group comprising biguanides, glucosidase inhibitors, PPARgamma modulators, dual PPARalpha/gamma agonists, RXR modulators, SGLT2 inhibitors, aP2 inhibitors, insulin sensitizers, GLP-1 or mimetics, DPPIV inhibitors, PTP-1B inhibitors, GSK-3 inhibitors and a metiglinide.

### Claim 15 (depends on 13)

Pharmaceutical composition according to claim 13, wherein the antidiabetic agent is selected from the group consisting of metformin, glyburide, glibenclamide, glimepiride, glypiride, glipizide, chlorpropamide, gliclazide, acarbose, miglitol, pioglitazone, troglitazone, rosiglitazone, insulin, isaglitazone, repaglinide, nateglinide, and exendin-4.

### Claim 16 (depends on 1)

Use of a bicyclic oligopeptide according to claim 1 for the preparation of a medicament for the treatment or prevention of diseases, in which glucagon receptors are involved.

### Claim 17 (depends on 1)

A method of treating diabetes mellitus comprised of the steps of administering to a patient in need thereof a therapeutically effective amount of a bicyclic oligopeptide according to claim 1.
